Work

Supplemental Table 3 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

Year: 2023

Type: supplementary-materials

Abstract: Quality of life (QoL) t-tests for all patients (A), GYN versus non-GYN patients (B) and patients who completed cycle 2 and those who did not (C).

DOI: 10.1158/1078-0432.22455381

Authors: Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker-Prietz, Robert J. Kinders, Lihua Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lillian L. Siu, Nilofer S. Azad

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361884009

Cites:

Cited by:

Related to: 10